Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Repare Therapeutics Inc
(NQ:
RPTX
)
3.210
+0.040 (+1.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Repare Therapeutics Inc
< Previous
1
2
3
Next >
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
June 26, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
June 10, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
June 04, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
May 29, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
May 07, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
April 30, 2024
From
Debiopharm
Via
Business Wire
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
April 30, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
April 26, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
February 29, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm
February 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
February 16, 2024
From
Kirby McInerney LLP
Via
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
February 15, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Regain Global Rights to Camonsertib
February 12, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
January 25, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
January 08, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
January 04, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
December 29, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
November 15, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
November 07, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
November 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
October 13, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 03, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 19, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Inc. (NASDAQ: RPTX) Near the Top of Equities by Percentage Gain on 8/10
August 10, 2023
Via
Investor Brand Network
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.